NASDAQ:KALA KALA BIO Q4 2025 Earnings Report $0.53 -0.14 (-20.89%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast KALA BIO EPS ResultsActual EPS$0.86Consensus EPS -$8.50Beat/MissBeat by +$9.36One Year Ago EPSN/AKALA BIO Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKALA BIO Announcement DetailsQuarterQ4 2025Date4/15/2026TimeBefore Market OpensConference Call DateWednesday, April 15, 2026Conference Call Time7:00AM ETUpcoming EarningsKALA BIO's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedulesConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) KALA BIO Earnings HeadlinesKala Bio Signs LOI With Virotek For Exclusive U.S. Distribution; Stock DownSeptember 1 at 2:28 PM | rttnews.comKala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing PartnershipSeptember 1 at 2:28 PM | finance.yahoo.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 1 at 1:00 AM | Base Camp Trading (Ad)Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing ProgramSeptember 1 at 7:45 AM | globenewswire.comBrokerages Set KALA BIO, Inc. (NASDAQ:KALA) Target Price at $1,158.33August 27, 2026 | americanbankingnews.comKALA BIO Announces Brief Delay in Quarterly FilingAugust 14, 2026 | tipranks.comSee More KALA BIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like KALA BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KALA BIO and other key companies, straight to your email. Email Address About KALA BIOKALA BIO (NASDAQ:KALA) (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis. Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions. These include formulations under development for dry eye disease and post-operative ocular inflammation, each leveraging the company’s nanoparticle platform to achieve higher local drug concentrations while potentially reducing systemic exposure. Preclinical and clinical programs are also exploring additional indications in retinal and anterior segment disorders. Founded in 2014 and headquartered in Watertown, Massachusetts, KALA Bio conducts research and development activities primarily in the United States. The company collaborates with academic institutions, specialty pharmacies and contract research organizations to support its clinical programs and regulatory filings. To broaden its global footprint, KALA Bio is evaluating strategic partnerships for potential expansion into European and Asian markets.View KALA BIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI MoatMedtronic’s Stars Are Aligning for a Price RecoverySalesforce Looks Overbought, But the Rally May Be Far From OverIs Abercrombie & Fitch's Hot Streak Just Getting Started?Dutch Bros Sell-Off Creates a Growth OpportunityQualcomm’s AI Ambitions Run Into a Smartphone Reality CheckPalantir’s Sovereign AI Pitch Tests Microsoft’s Cloud-First AI Bet Upcoming Earnings Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
